Mon, May 12, 12:16 PM (42 days ago)
**Imunon, Inc. (IMNN) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** Imunon, Inc. reported no revenue for Q1 2025, consistent with previous quarters due to its clinical-stage biotechnology focus. - **Net Loss:** The company reported a net loss of $4.1 million for Q1 2025, a slight improvement from the $4.9 million loss in Q1 2024. - **Operating Expenses:** Total operating expenses decreased by 17.3% to $4.1 million in Q1 2025 from $5.0 million in Q1 2024. Research and development (R&D) expenses decreased by 34.3% to $2.2 million, while general and administrative expenses increased by 15.3% to $2.0 million. - **Cash Flow:** Net cash used in operating activities was $2.8 million in Q1 2025, compared to $5.9 million in Q1 2024. The company had $2.9 million in cash and cash equivalents at the end of Q1 2025. - **Profit Margins:** Not applicable due to the lack of revenue. **Key Metrics and Trends:** - **Cash Position:** Imunon's cash position remains a concern, with only $2.9 million in cash and cash equivalents at the end of Q1 2025. The company has substantial future capital requirements to continue its research and development activities. - **Funding:** Imunon continues to seek additional capital through equity offerings, debt financing, and strategic alliances. The company sold 120,047 shares of common stock for net proceeds of $105,693 in Q1 2025. - **Going Concern:** The company's financial statements include a going concern note, indicating substantial doubt about its ability to continue as a going concern. **Future Operations and Impact:** - **Clinical Trials:** Imunon is advancing its lead clinical program, IMNN-001, a DNA-based immunotherapy for ovarian cancer, through a Phase 3 pivotal trial. The company is also developing a COVID-19 booster vaccine, IMNN-101, which has shown promising results in a Phase 1 trial. - **Uncertainties:** The company faces uncertainties related to the success of its clinical trials, regulatory approvals, and its ability to raise additional capital. The global economic climate and geopolitical events may also impact its operations and funding efforts. **Conclusion:** Imunon, Inc. continues to focus on advancing its clinical programs, but its financial health remains a concern. The company's ability to secure additional funding and successfully complete its clinical trials will be crucial for its future operations and potential commercialization of its drug candidates.